

Does HIV Coinfection Affect HCV Reimbursement Decisions?

November 2019



Presenter: Yulia Privolnev
Senior Manager, Global Access


Author: Nafkote Gizaw, MPH
Analyst, Context Matters

Contributing Authors:
Judith Rubinstein, MPA
Rachel Sliman, MPH
Christine Zacarelli
Boaz Adler, MPA
Erin Guill, MBA

Background and Research Objective

Does HIV Coinfection Affect HCV Reimbursement Decisions?


Global Disease Burden by Region, 2017



- Thirty-seven million people are infected with human immunodeficiency virus (HIV). Approximately 115 million people have hepatitis C virus (HCV) infection.
- The odds of contracting HCV infection are 6 times higher among patients with HIV.

Platt, Lucy, et al. "Prevalence and Burden of HCV Co-Infection in People Living with HIV: A Global Systematic Review and Meta-Analysis." *The Lancet Infectious Diseases*, vol. 16, no. 7, 24 Feb. 2016, pp. 797–808., doi:10.1016/s1473-3099(15)00485-5.


HCV Genotypes and Targeted Therapies by Drug Class



Therapy by Drug Class	Targeted Genotype
Interferons	
peginterferon alfa-2a	genotype 1
peginterferon alfa-2b	genotype 1, 2, or 3
Protease inhibitors (in combination with peginterferon + ribavirin)	
telaprevir	genotype 1
simeprevir	genotype 1 or 4
Polymerase inhibitors (in combination with peginterferon + ribavirin)	
sofosbuvir	genotype 1
Interferon-free regimens	
simeprevir + sofosbuvir	genotype 1 or 4
sofosbuvir-velpatasvir	genotypes 1 to 6
Nucleoside analogues	
ribavirin	genotype 1, 2, or 3

Gower, Erin, et al. "Global Epidemiology and Genotype Distribution of the Hepatitis C Virus Infection." Journal of Hepatology, vol. 61, no. 1, Nov. 2014, doi:10.1016/j.jhep.2014.07.027.

Health Technology Assessment



Agencies Covered	
	Canadian Agency for Drugs and Technologies in Health (CADTH)
	Gemeinsamer Bundesausschuss (G-BA)
	Haute Autorité de Santé (HAS)
	National Institute for Health and Care Excellence (NICE)
	Pharmaceutical Benefits Advisory Committee (PBAC)
	Scottish Medicines Consortium (SMC)

Objective: To assess whether including HIV-coinfected patient subgroup analyses play a role in receiving positive reimbursement decisions in health technology assessment (HTA) submissions for HCV treatments.

Methodology

Does HIV Coinfection Affect HCV Reimbursement Decisions?

Data-Selection Process

Data extracted from the
Context Matters Platform
between 2009 and 2018

All HCV reimbursement
decisions among adult
and pediatric populations

(n = 456)

Selected agencies:
CADTH, G-BA, HAS,
NICE, PBAC, SMC
(n = 325)



Positive and
negative
reimbursement
decisions
(n = 288)



Adult HCV patients,
including those with
HIV coinfection

(n = 434)


Excluding
abbreviated and
non-submissions

(n = 312)

Results and Conclusion

Does HIV Coinfection Affect HCV Reimbursement Decisions?


Distribution of All Reimbursement Decisions



Of the 6 HTA agencies, NICE and G-BA assessed HCV therapies at higher rates, while CADTH had the lowest rate.


Decision for All HCV Therapies

■ Positive (n = 244) ■ Negative (n = 44)



Among all HCV therapies that were evaluated for reimbursement, approximately 85% received positive decisions between 2009 and 2018.


Distribution of Reimbursement Decisions by Agency



G-BA made the most positive HCV decisions (100% [n = 70]), followed by HAS (97.6% [n = 40]), and CADTH (94.44% [n = 17]).

Relationship Between Reimbursement Decision and Type of Therapy

Decision by Target Population
for HCV Therapies



- Fisher's exact test demonstrated that there is no significant relationship between receiving positive reimbursement decisions and HTA submissions for HCV therapies that included an HIV-coinfected subgroup ($p = 0.1558$).

Target Population for HCV Therapy	Reimbursement Decision		Total
	Recommend (%)	Do not recommend (%)	
HCV	84.12	15.88	277
HCV-HIV Coinfection	100	0	11

Timeline of First Reimbursement Approvals of Therapies for Patients with HCV and HCV-HIV Coinfection



Why Were HCV Therapies Recommended for HIV-Coinfected Patients?

Grounds for Approval by Drug Class, by Population

	Interferons	Interferon-free Regimens
Drugs	Pegasys (<i>peginterferon alfa-2a + ribavirin</i>)	Viekirax (<i>ombitasvir-paritaprevir-ritonavir ± ribavirin or dasabuvir</i>) Harvoni (<i>ledipasvir-sofosbuvir</i>)
Population	Genotype 1 HCV with HIV coinfection	Genotype 1 HCV with HIV coinfection
Reasons for Reimbursement	- Cost-effective  - Dominant ICERs (< £12,000/QALY)  - Curative therapy 	Hint of an additional clinical benefit over comparators (peginterferon alfa + ribavirin) 

Grounds for Approval by Drug Class, by Population (Cont'd)

	Protease Inhibitors (+ peginterferon + ribavirin)	Polymerase Inhibitors (+ peginterferon + ribavirin)
Drugs	Galexos, Olysio (<i>simeprevir</i>)	Sovaldi (<i>sofosbuvir</i>)
Population	Genotype 1 or 4 HCV with HIV coinfection	- Genotypes 1 to 6 HCV with HIV coinfection - Genotypes 1 to 6 HCV with HIV coinfection (except genotype 3)
Reasons for Reimbursement	- Similar efficacy (sustained virological response rate) as seen in HCV patients  - Higher efficacy and better safety profile   - Short treatment duration  - Lower cost over comparator (telaprevir + peginterferon alfa-2a), higher QALY gains 	- Indication of a minor benefit over the comparator, peginterferon alfa-2a + ribavirin  - Higher efficacy: virological levels  - Better safety profile in most difficult-to-treat patients (genotypes 1, 4, 5, and 6) and cirrhotic patients, no drug interactions 

Conclusion and Key Takeaways

1

All HCV therapies for patients coinfectd with HIV were recommended.

2

Expanding the HCV demographic to include HIV-coinfectd patients for HCV therapies does not reduce the rate of positive reimbursement decisions.

3

Whether or not including an HIV-coinfectd subgroup increases the rate of receiving positive decisions is not clear given the small sample size.



Thank you!

For questions, contact:

Nafkote Gizaw, MPH

nafkote.gizaw@contextmatters.com